Nitisinone
FDA-approved product (capsule, oral), marketed as Harliku, Nitisinone, Nityr and 1 more.
- Registered studies
- 17
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Tyrosinemia
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Various alimentary tract and metabolism products
- FDA pharmacologic class
- 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
17registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nitisinone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ziprasidone MesylateExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more50.3% AI-predicted activityagainst E. coli50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm50.2% AI-predicted activityagainst E. coli50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more50.2% AI-predicted activityagainst E. coli50+ registered studies
- GefitinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.1% AI-predicted activityagainst E. coli50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma50.0% AI-predicted activityagainst E. coli40 registered studies
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more50.0% AI-predicted activityagainst E. coli50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis49.8% AI-predicted activityagainst E. coli28 registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more49.8% AI-predicted activityagainst E. coli50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis49.8% AI-predicted activityagainst E. coli2 registered studies
- Fosdenopterin HydrobromideExisting use: Inborn metal metabolism disorder, Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A49.7% AI-predicted activityagainst E. coliNo documented evidence found
- NevirapineExisting use: HIV infection, HIV-1 infection, Viral disease49.7% AI-predicted activityagainst E. coli50+ registered studies
- Lapatinib DitosylateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more49.6% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Long-Term Study of Nitisinone to Treat Alkaptonuria
NCT00107783 · start 2005-01
Registered record
- Registry ID
- NCT00107783
- Conditions
- Alkaptonuria
- Interventions
- Nitisinone (NTBC)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2009-04
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlkaptonuriaInterventionNitisinone (NTBC)PhasePhase 2Registry statusCompletedPrevention of Dichloroacetate Toxicity
NCT00031161 · start 2001-09
Registered record
- Registry ID
- NCT00031161
- Conditions
- Acidosis, Lactic; Chronic Disease
- Interventions
- Nitisinone (NTBC); Dichloroacetate; Low-tyrosin diet
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2001-09
- Completion
- 2005-09
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcidosis, Lactic; Chronic DiseaseInterventionNitisinone (NTBC); Dichloroacetate; Low-tyrosin dietPhaseNot applicableRegistry statusCompleted